Literature DB >> 8636740

Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.

K Hellmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636740     DOI: 10.1200/JCO.1996.14.2.332

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].

Authors:  H Sauer
Journal:  Strahlenther Onkol       Date:  1997-01       Impact factor: 3.621

Review 3.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 4.  Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.

Authors:  Diana Iarussi; Paolo Indolfi; Fiorina Casale; Vincenzo Martino; Maria Teresa Di Tullio; Raffaele Calabrò
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Anthracyclines in the treatment of cancer. An overview.

Authors:  G N Hortobágyi
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.